BioSpace News Archive

Altavant Sciences , a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, presented an update on the clinical development of rodatristat ethyl

Koya Medical , a healthcare company focused on developing breakthrough treatments for lymphedema and venous diseases, will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021 .

Incyte announced that it will present at the following investor conferences during the month of June

ITM to Host Virtual Symposium on “New Approaches for Targeted Radionuclide Therapy in Precision Oncology” with Key Opinion Leaders on Friday, June 4 th , 2021 in Parallel to 2021 ASCO Annual Meeting

-- Combined E1A and E4-ORF6/7 mutations demonstrate high degree of tumor selectivity in lead product candidate ICVB-1042 (formerly IOV-1042) -- -- IND filing for ICVB-1042 expected 1H 2022 -- -- Data published online in ASCO 2021 Annual Meeting Proceedings --

Medeor Therapeutics, Inc. , a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced that interim results of ts Phase 3 study clinical trial for MDR-101 cell therapy

- 12-month overall survival (OS) : 60% (n=6/10) in VBI-1901 + GM-CSF study arm compared to historical controls of ~30% 1 – 12-month OS not yet reached with VBI-1901 + AS01 B 2 - 6-month OS : 80%+ survival achieved across both study arms compared to historical controls of ~60% 1 - 2 partial tumor responses and 7 stable disease observations across both study arms - Full data to be highlighted in ASCO poster presentation June 4-8, 2021

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that David Arkowitz will join as Executive Vice President, Chief Financial Officer (CFO) and Head of Business Development, effective June 1, 2021. Mr. Arkowitz will report directly to Eric Shaff, President and Chief Executive Officer of Seres.

Sparta Group has signed a Memorandum of Understanding, with CASPR Group of Addison TX to formalize an exclusive distribution and development agreement, for the North American transportation sector, between Sparta’s TruckSuite™ division and CASPR™, as well as to develop a non-exclusive agreement between Sparta Health Group and CASPR™.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the following investor conferences. William Blair 41 st Annual Growth Stock Conference Fireside Chat on Tuesday, June 1 st at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time